In CNS trials, high placebo rates have been blamed for the late-stage failure of promising treatments. Many industry-sponsored CNS trials today include at least one and usually multiple mechanisms to minimize placebo response. This whitepaper:
- Describes the causes of placebo response
- Examines frequently used placebo response mitigation strategies
- Discusses their effectiveness.